$3.75
Revenue is up for the last 2 quarters, 37.0K → 182.0K (in $), with an average increase of 79.7% per quarter
Netprofit is down for the last 4 quarters, 83.0K → -10.99M (in $), with an average decrease of 2441.6% per quarter
In the last 1 year, Novo Nordisk A/s has given 283.9% return, outperforming this stock by 269.0%
In the last 3 years, Novo Nordisk A/s has given 452.1% return, outperforming this stock by 506.3%
1.33%
Downside
Day's Volatility :7.33%
Upside
6.08%
46.13%
Downside
52 Weeks Volatility :76.78%
Upside
56.9%
Period | Verrica Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -34.75% | 0.0% | 0.0% |
6 Months | -37.21% | 3.0% | -0.5% |
1 Year | 14.94% | 7.2% | 0.4% |
3 Years | -54.18% | 27.5% | 19.1% |
Market Capitalization | 194.8M |
Book Value | $1.32 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.45 |
Wall Street Target Price | 12.67 |
Profit Margin | -272.23% |
Operating Margin TTM | -272.72% |
Return On Assets TTM | -23.35% |
Return On Equity TTM | -65.32% |
Revenue TTM | 8.6M |
Revenue Per Share TTM | 0.2 |
Quarterly Revenue Growth YOY | -15.0% |
Gross Profit TTM | 8.3M |
EBITDA | -22.9M |
Diluted Eps TTM | -0.45 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.21 |
EPS Estimate Next Year | -1.02 |
EPS Estimate Current Quarter | -0.21 |
EPS Estimate Next Quarter | -0.33 |
What analysts predicted
Upside of 237.87%
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Verrica Pharmaceuticals Inc | -8.47% | -37.21% | 14.94% | -54.18% | -75.49% |
![]() Moderna, Inc. | -6.8% | -31.93% | -17.68% | 49.48% | 456.61% |
![]() Regeneron Pharmaceuticals, Inc. | -1.51% | 9.46% | 20.83% | 45.51% | 113.13% |
![]() Novo Nordisk A/s | 2.93% | 159.64% | 287.41% | 451.49% | 693.95% |
![]() Seagen, Inc. | 7.08% | 3.54% | 46.23% | 13.76% | 163.58% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 16.4% | 23.04% | 33.45% | 95.64% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Verrica Pharmaceuticals Inc | NA | NA | NA | -1.21 | -0.65 | -0.23 | 0.0 | 1.32 |
![]() Moderna, Inc. | 39.67 | 39.67 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.65 | 21.65 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 44.47 | 44.47 | 2.03 | 3.32 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.47 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.73 | 26.73 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Verrica Pharmaceuticals Inc | Buy | $194.8M | -75.49% | NA | -272.23% |
![]() Moderna, Inc. | Buy | $39.4B | 456.61% | 39.67 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.3B | 113.13% | 21.65 | 33.93% |
![]() Novo Nordisk A/s | Buy | $423.8B | 693.95% | 44.47 | 33.4% |
![]() Seagen, Inc. | Hold | $38.9B | 163.58% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.9B | 95.64% | 26.73 | 35.4% |
Perceptive Advisors LLC
venBio Select Advisor LLC
Vanguard Group Inc
FMR Inc
BlackRock Inc
Geode Capital Management, LLC
Verrica Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read Moreverrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Organization | Verrica Pharmaceuticals Inc |
Employees | 22 |
CEO | Mr. Ted White |
Industry | Health Technology |
Bluebird Bio, Inc.
$3.75
-6.25%
Abvc Biopharma Inc
$3.75
-6.25%
Fidelity Stocks For Inflation Etf
$3.75
-6.25%
Wisdomtree Smallcap Earnings Etf
$3.75
-6.25%
Madison Square Garden Entertainment Corp
$3.75
-6.25%
Corbus Pharmaceuticals Holdings, Inc.
$3.75
-6.25%
Abrdn Emerging Markets Equity Income Fund Inc
$3.75
-6.25%
Sangamo Therapeutics, Inc.
$3.75
-6.25%
Sight Sciences Inc
$3.75
-6.25%